Found 385 matching trials
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
NAThis is a Prospective, Multicenter, Randomized Controlled study to evaluate...
Location
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
N/ALung cancer (LC) is the tumor responsible for the highest mortality worldwi...
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
PHASE2Leptomeningeal metastasis (LM) is a devastating and terminal complication o...
Location
Multiple Locations
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
N/ATo estimate parameters related to clinical outcomes in a real-world seeting...
Status
Active Not Recruiting
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
PHASE2This is a single-center, open-label, phase I clinical trial aimed to evalua...
Location
Tianjin Medical University Cancer Institute and Hospital
AZD9291 First Time In Patients Ascending Dose Study
PHASE1This study will treat patients with advanced NSCLC who have already receive...
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
PHASE2This open-label, multicenter, randomized phase II study will evaluate the u...
Status
Active Not Recruiting
Location
BC Cancer, Vancouver Centre
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
PHASE1BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multipl...
Status
Active Not Recruiting
Location
University of Alabama
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
PHASE1The purpose of this randomized study is to determine the safety and efficac...
Location
Valkyrie Clinical Trials
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
PHASE1The purpose of this study is to evaluate the safety, tolerability, pharmaco...
Location
Honor Health Research Institute